10x Genomics, Inc. — Director's Dealing 2021

Nov 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-11-01

Reporting Person: Hindson Benjamin J. (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-01	Class A Common Stock	M	10232	$5.04	Acquired	57349	Direct
2021-11-01	Class A Common Stock	M	31434	$11.48	Acquired	88783	Direct
2021-11-01	Class A Common Stock	S	1100	$160.5036	Disposed	87683	Direct
2021-11-01	Class A Common Stock	S	1500	$162.0606	Disposed	86183	Direct
2021-11-01	Class A Common Stock	S	11829	$163.1541	Disposed	74354	Direct
2021-11-01	Class A Common Stock	S	24125	$163.8672	Disposed	50229	Direct
2021-11-01	Class A Common Stock	S	3112	$164.7514	Disposed	47117	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Stock Option (right to buy)	$5.04	M	10232	Disposed	2028-11-02	Class A Common Stock (10232)	Direct
2021-11-01	Stock Option (right to buy)	$11.48	M	31434	Disposed	2029-05-10	Class A Common Stock (31434)	Direct

Footnotes

F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2: This transaction was executed in multiple trades at prices ranging from $160.00 to $160.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $161.45 to $162.43. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $162.48 to $163.475. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $163.48 to $164.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $164.50 to $165.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F7: This option, originally for 175,000 shares, of which 124,116 shares have been exercised, vested as to 1/48th of the shares on October 1, 2018 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F8: This option, originally for 100,000 shares, of which 31,434 shares have been exercised, vested as to 1/48th of the shares on May 1, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.